Press release
Particle-Enhanced Turbidimetric Immunoassay Market Worth Is Likely To Grow At 4.3% By 2031
Between 2021 and 2031, the market for particle-enhanced turbidimetric immunoassays (PETIA) is anticipated to increase rapidly. Some of the key elements propelling the market for particle-enhanced turbidimetric immunoassays are the rising incidence of infectious disorders and the expanding interest in medical research.Recently, medical professionals and researchers have become very interested in PETIA. This method provides a number of benefits. It is perfect for quantitative measurements of proteins, pathogens, and other compounds in bodily fluids including urine, plasma, and serum because of how quickly and affordably it can be done.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.factmr.com/connectus/sample?flag=S&rep_id=6899?PS
Due to the quick and reliable antibody-antigen interaction that occurs during PETIA, it has been frequently employed in clinical diagnostics to quantify hundreds of circulating proteins. Ready-to-use PETIA kits have been created by a number of medical organisations and businesses, including ImmunoDiagnostics Limited (IMD), to aid in the risk assessment and diagnosis of chronic diseases.
Increasing funding by government and other healthcare organization will expand the PETIA market during the forecast period. As per Fact.MR, the hospital segment is poised to emerge as the leading end user for PETIA products during the forecast period.
North America leads the PETIA market as a result of increasing prevalence of infectious diseases, presence of leading players, and recent advances in the medical research.
"Particle-enhanced turbidimetric immunoassays' flexibility make it ideal for integration with chemical analyzers in laboratory infrastructure. The technique is therefore increasingly used to get desired reading within a couple of minutes from its initiation, thus increasing the number of samples analyzed on a daily basis," says the Fact.MR analyst.
๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ ๐๐ซ๐จ๐ฆ ๐๐๐ซ๐ญ๐ข๐๐ฅ๐-๐๐ง๐ก๐๐ง๐๐๐ ๐๐ฎ๐ซ๐๐ข๐๐ข๐ฆ๐๐ญ๐ซ๐ข๐ ๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐๐ฌ๐ฌ๐๐ฒ๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ฎ๐ซ๐ฏ๐๐ฒ
With high prevalence of infectious diseases and presence of advanced healthcare and research setups, North America dominates the PETIA market.
The U.S. is emerging as the most lucrative market for PETIA. The robust growth in the country can be attributed to the presence of leading market players and international medical research organizations.
The Europe market is poised to exhibit high demand as research initiatives for novel drug discovery pick up pace in the U.K. and Germany.
Diagnosis of infectious disease remains the leading application for PETIA technique.
Hospitals are expected to emerge as the leading end user for PETIA during the forecast period.
๐๐๐ฒ ๐๐ซ๐ข๐ฏ๐๐ซ๐ฌ
โข Increasing prevalence of various diseases is mainly driving the PETIA market.
โข Advances in medical research is positively impacting the market growth.
โข Low cost and shorter time-to-result of PETIA makes it more preferred as compared to its counterparts.
โข Rising geriatric population is expected to create huge demand for PETIA during the forecast period.
โข COVID-19 pandemic supported the market growth as various companies started to develop testing kits using PETIA technology.
๐๐๐ฒ ๐๐๐ฌ๐ญ๐ซ๐๐ข๐ง๐ญ๐ฌ
Lack of awareness about this novel technique across developing and underdeveloped countries is hampering the growth of PETIA market.
Low penetration of PETIA products also impacts the market growth.
๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐๐๐ง๐๐ฌ๐๐๐ฉ๐
Key players operating in the PETIA market are focusing on developing novel products using PETIA technique. They have developed various strategies such as advanced product launch, mergers and acquisitions to stay relevant in the market and expand their presence.
In August 2020, Gentian Diagnostics ASA added the Gentian Calprotectin Immunoassay (GCAL), the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation, to its catalogue.
In August 2020, TRIMERO Dianostics added new Serum Amyloid A, CE-IVD marked, particle-enhanced turbidimetric immunoassay to its catalogue.
In August 2020, Genetian Diagnostics ASA announced that it will launch COVID-19 antibody test using its unique PETIA technology. The Genetian antibody test will be a turbidimetric COVID-19 assay using the PETIA technology.
๐๐จ๐ฆ๐ ๐จ๐ ๐ญ๐ก๐ ๐ฉ๐ซ๐จ๐ฆ๐ข๐ง๐๐ง๐ญ ๐ฆ๐๐ง๐ฎ๐๐๐๐ญ๐ฎ๐ซ๐๐ซ๐ฌ ๐๐ง๐ ๐ฌ๐ฎ๐ฉ๐ฉ๐ฅ๐ข๐๐ซ๐ฌ ๐จ๐ฉ๐๐ซ๐๐ญ๐ข๐ง๐ ๐ข๐ง ๐ญ๐ก๐ ๐ฉ๐๐ซ๐ญ๐ข๐๐ฅ๐-๐๐ง๐ก๐๐ง๐๐๐ ๐ญ๐ฎ๐ซ๐๐ข๐๐ข๐ฆ๐๐ญ๐ซ๐ข๐ ๐ข๐ฆ๐ฆ๐ฎ๐ง๐จ๐๐ฌ๐ฌ๐๐ฒ๐ฌ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฉ๐ซ๐จ๐๐ข๐ฅ๐๐ ๐๐ฒ ๐ ๐๐๐ญ.๐๐ ๐๐ซ๐:
Gentian Diagnostics ASA
Eurospital
Calpro
Thermo-Fisher Scientific
Buehlmann
Biotec
Abbott Laboratories
F.Hoffmann-La Roche
Siemens AG
Danaher Corporation
Diasorin SPA
Sysmex Corporation
Biomerieux SA
QIAGEN
Agilent Technologies, Inc
A PETIA prototype that can measure the amounts of calprotectin in serum or plasma was created by researchers at Uppsala University in Norway. Since calprotectin is referred to as the body's inflammation marker, this technology can be utilised to measure its levels in inflammatory bowel problems. Such novel approaches to already-available technologies are what will steer the market in a lucrative path.
๐๐๐ญ ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐๐ญ๐ข๐จ๐ง ๐จ๐ง ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐จ๐ซ ๐๐ฉ๐๐๐ข๐๐ข๐ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=6899?PS
๐๐จ๐ซ๐ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ ๐จ๐ง ๐ญ๐ก๐ ๐๐ฅ๐จ๐๐๐ฅ ๐๐๐ซ๐ญ๐ข๐๐ฅ๐-๐๐ง๐ก๐๐ง๐๐๐ ๐๐ฎ๐ซ๐๐ข๐๐ข๐ฆ๐๐ญ๐ซ๐ข๐ ๐๐ฆ๐ฆ๐ฎ๐ง๐จ๐๐ฌ๐ฌ๐๐ฒ๐ฌ ๐๐๐ฅ๐๐ฌ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค
Fact.MR provides an unbiased analysis of particle-enhanced turbidimetric immunoassays market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand PETIA with a detailed segmentation on the basis of:
Application:
Infectious Diseases
Endocrinology
Cardiology
Oncology
Bone and Mineral Diseases
Autoimmune Disorders
Others
End User:
Hospitals
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Others
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Contact:
Us Sales Office :
11140 Rockville Pike
Suite 400
Rockville, Md 20852
United States
Tel: +1 (628) 251-1583
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Particle-Enhanced Turbidimetric Immunoassay Market Worth Is Likely To Grow At 4.3% By 2031 here
News-ID: 3173508 • Views: โฆ
More Releases from Fact.MR
European Permanent Magnets Industry Analysis in the USA Outlook 2025-2035: Key D โฆ
The United States permanent magnets industry is projected to expand from an estimated US$ 5.28 billion in 2025 to approximately US$ 9.01 billion by 2035, achieving a steady CAGR of about 5.5% over the forecast decade. High-performance magnet types-especially neodymium-iron-boron (NdFeB)-are expected to remain the dominant material, accounting for roughly half of all U.S. demand in 2025. The automotive sector, led by electric vehicle (EV) growth, is forecast to retainโฆ
European Nutraceutical Packaging Market Outlook 2025-2035: Key Developments and โฆ
The European nutraceutical packaging market is forecast to grow robustly from an estimated US$ 1.4 billion in 2025 to nearly US$ 2.3 billion by 2035, expanding at a projected CAGR of approximately 4.8%. Strong supplement consumption, eco-friendly packaging investments, and advanced production technologies are expected to be the primary catalysts for this decade-long expansion.
As Europe's population becomes increasingly health-conscious and preventive healthcare gains widespread traction, demand for vitamins, minerals, herbalโฆ
European Fluorosurfactant Market Outlook 2025-2035: Key Developments and Future โฆ
The European fluorosurfactant market is projected to experience strong growth between 2025 and 2035 - nearly doubling in value over the decade. This uptrend is being driven by rising demand from high-performance coatings, adhesives, electronics, and industrial sectors, coupled with increasing pressure to develop more environmentally sustainable fluorinated surfactants.
Key Growth Drivers
High-Performance Applications:
Fluorosurfactants are prized for their exceptional wetting, levelling, and low surface tension properties, making them indispensable in specialty coatings,โฆ
European Cell Culture Vessels Market Outlook 2025-2035: Key Developments and Fut โฆ
The European cell culture vessels market is poised for robust growth between 2025 and 2035, driven by a sharp uptick in biopharmaceutical research, the growing popularity of single-use systems, and increasing regulatory momentum around advanced therapies.
By 2030, the European cell culture vessels market could reach over US$ 3 billion, underpinned by a projected compound annual growth rate (CAGR) in double digits. This trajectory underscores how critical innovative cell culture platformsโฆ
More Releases for PETIA
Particle-Enhanced Turbidimetric Immunoassay Market to Reach $5.05 Billion by 203 โฆ
The global particle-enhanced turbidimetric immunoassay market is valued at an estimated US$ 2.03 billion in 2024. It is expected to grow at a CAGR of 9.6%, reaching US$ 5.05 billion by 2034.
The particle-enhanced turbidimetric immunoassay (PETIA) market is gaining significant traction in the global healthcare and diagnostics industry. PETIA is a widely used immunoassay technique that enhances sensitivity and accuracy in detecting specific proteins, hormones, and biomarkers in biological samples.โฆ
Cystatin C Assay Market Grows with Applications in Early Kidney Disease Detectio โฆ
"Global Cystatin C Assay Market, By Product (Analyzers, Kits & Reagents), Method (ELISA, PETIA, IFA, CLIA, PENIA), Application (Diagnostics, Research), Sample Type (Blood, Urine), End User (Hospitals, Clinical Laboratories, Others), Distribution Channel (Direct Tenders, Retail Sales) - Industry Trends and Forecast to 2031.
Data Bridge Market Research analyses that the Global Cystatin C Assay Market which was USD 224.8 Million in 2023 is expected to reach USD 401.64 Billion by 2031โฆ
Particle Enhanced Turbidimetric Immunoassay Market Trends and Analysis - Opportu โฆ
Market Overview and Report Coverage
Particle Enhanced Turbidimetric Immunoassay (PETIA) is a highly sensitive immunoassay technique used for the quantification of various analytes in biological samples. This method utilizes the principle of turbidimetry, where the intensity of light scattered by particles in a solution is measured to determine the concentration of the analyte of interest.
The PETIA market is expected to grow at a CAGR of 5.50% during the forecasted period. Theโฆ
Cystatin C Assay Kit (PETIA) Market 2023 Perception, Extension and Predicted Tre โฆ
The Cystatin C Assay Kit (PETIA) research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Cystatin C Assay Kit (PETIA) research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and drivingโฆ
Particle Enhanced Tubidimetric Immunoassay (PETIA) Market Trends and Growth Repo โฆ
Particle Enhanced Tubidimetric Immunoassay (PETIA) is gaining significant traction in the diagnostics and healthcare industry due to its precision and efficiency in detecting various diseases and conditions. This market research report provides a comprehensive analysis of the PETIA market, covering key players, segmentation, market growth, and segment analysis.
According to Reports and Insights analysis, the particle enhanced turbidimetric immunoassay (petia) market is expected to register a CAGR of 5.8% during theโฆ
Renal Biomarkers Market Booming by Size, Revenue and Trend in 2019
Renal biomarkers help diagnose or identify the patients at risk of developing kidney diseases, by measuring their blood or urine levels. They are commonly released in acute or chronic kidney injuries, which are characterized by the rapid or gradual loss of kidney function resulting into serous clinical implications.
Download the Sample Report @ http://bit.ly/2WPpJBJ
There is an impending need for specific and sensitive biomarkers that can identify kidney diseases at theโฆ
